Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments
The prevalence of obesity and diabetes mellitus (DM) has been consistently increasing worldwide. Sharing powerful genetic and environmental features in their pathogenesis, obesity amplifies the impact of genetic susceptibility and environmental factors on DM. The ectopic expansion of adipose tissue...
Saved in:
Published in | Frontiers in endocrinology (Lausanne) Vol. 14; p. 1161521 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
Frontiers Media S.A
21.04.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The prevalence of obesity and diabetes mellitus (DM) has been consistently increasing worldwide. Sharing powerful genetic and environmental features in their pathogenesis, obesity amplifies the impact of genetic susceptibility and environmental factors on DM. The ectopic expansion of adipose tissue and excessive accumulation of certain nutrients and metabolites sabotage the metabolic balance via insulin resistance, dysfunctional autophagy, and microbiome-gut-brain axis, further exacerbating the dysregulation of immunometabolism through low-grade systemic inflammation, leading to an accelerated loss of functional β-cells and gradual elevation of blood glucose. Given these intricate connections, most available treatments of obesity and type 2 DM (T2DM) have a mutual effect on each other. For example, anti-obesity drugs can be anti-diabetic to some extent, and some anti-diabetic medicines, in contrast, have been shown to increase body weight, such as insulin. Meanwhile, surgical procedures, especially bariatric surgery, are more effective for both obesity and T2DM. Besides guaranteeing the availability and accessibility of all the available diagnostic and therapeutic tools, more clinical and experimental investigations on the pathogenesis of these two diseases are warranted to improve the efficacy and safety of the available and newly developed treatments. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 ORCID: Rexiati Ruze, orcid.org/0000-0002-0891-5307; Tiantong Liu, orcid.org/0000-0002-3780-9431; Xi Zou, orcid.org/0000-0003-1224-6457; Jianlu Song, orcid.org/0000-0001-7181-2266; Yuan Chen, orcid.org/0000-0003-0449-1356; Ruiyuan Xu, orcid.org/0000-0003-4786-6330; Xinpeng Yin, orcid.org/0000-0002-5069-4421; Qiang Xu, orcid.org/0000-0002-6785-7178 Edited by: Inês Cebola, Imperial College London, United Kingdom Reviewed by: Etinne Sochett, University of Toronto, Canada; Peng Zhang, Affiliated Beijing Friendship Hospital, Capital Medical University, China These authors have contributed equally to this work This article was submitted to Diabetes: Molecular Mechanisms, a section of the journal Frontiers in Endocrinology |
ISSN: | 1664-2392 1664-2392 |
DOI: | 10.3389/fendo.2023.1161521 |